Evidence map›Paper›PMID 21914795›Full record

ArticleThe Journal of biological chemistry2011

The Ca2+-ATPase (SERCA1) is inhibited by 4-aminoquinoline derivatives through interference with catalytic activation by Ca2+, whereas the ATPase E2 state remains functional.

Gianluca Bartolommei, Francesco Tadini-Buoninsegni, Maria Rosa Moncelli, Sandra Gemma, Caterina Camodeca, Stefania Butini, Giuseppe Campiani, David Lewis, Giuseppe Inesi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Drug Interactions With the CaFrontiers in molecular biosciences · 2018
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Gianluca BartolommeiDepartment of Chemistry "Ugo Schiff," University of Florence, 50019 Sesto Fiorentino, Italy.
Francesco Tadini-BuoninsegniDepartment of Chemistry "Ugo Schiff," University of Florence, 50019 Sesto Fiorentino, Italy. Electronic address: francesco.tadini@unifi.it.
Maria Rosa MoncelliDepartment of Chemistry "Ugo Schiff," University of Florence, 50019 Sesto Fiorentino, Italy.
Sandra GemmaEuropean Research Centre for Drug Discovery and Development and Department of Pharmaceutical and Applied Chemistry, University of Siena, 53100 Siena, Italy.
Caterina CamodecaEuropean Research Centre for Drug Discovery and Development and Department of Pharmaceutical and Applied Chemistry, University of Siena, 53100 Siena, Italy.
Stefania ButiniEuropean Research Centre for Drug Discovery and Development and Department of Pharmaceutical and Applied Chemistry, University of Siena, 53100 Siena, Italy.
Giuseppe CampianiEuropean Research Centre for Drug Discovery and Development and Department of Pharmaceutical and Applied Chemistry, University of Siena, 53100 Siena, Italy.
David LewisCalifornia Pacific Medical Center Research Institute, San Francisco, California 94107.
Giuseppe InesiCalifornia Pacific Medical Center Research Institute, San Francisco, California 94107.
University of Siena · ITCalifornia Pacific Medical Center · USUniversity of Florence · IT

Funding

PHS HHS R0301-69830
6 · The paper itself

Abstract

Several clotrimazole (CLT) and 4-aminoquinoline derivatives were synthesized and found to exhibit in vitro antiplasmodial activity with IC(50) ranging from nm to μm values. We report here that some of these compounds produce inhibition of rabbit sarcoplasmic reticulum Ca(2+)-ATPase (SERCA1) with IC(50) values in the μm range. The highest affinity for the Ca(2+)-ATPase was observed with NF1442 (N-((3-chlorophenyl)(4-((4-(7-chloroquinolin-4-yl)piperazin-1-yl)methyl)phenyl)methyl)-7-chloro-4-aminoquinoline) and NF1058 (N-((3-chlorophenyl)(4-(pyrrolidin-1-ylmethyl)phenyl)methyl)-7-chloro-4-aminoquinoline),yielding IC(50) values of 1.3 and 8.0 μm as demonstrated by measurements of steady state ATPase activity as well as single cycle charge transfer. Characterization of sequential reactions comprising the ATPase catalytic and transport cycle then demonstrated that NF1058, and similarly CLT, interferes with the mechanism of Ca(2+) binding and Ca(2+)-dependent enzyme activation (E(2) to E(1)·Ca(2) transition) required for formation of phosphorylated intermediate by ATP utilization. On the other hand, Ca(2+) independent phosphoenzyme formation by utilization of P(i) (i.e. reverse of the hydrolytic reaction in the absence of Ca(2+)) was not inhibited by NF1058 or CLT. Comparative experiments showed that the high affinity inhibitor thapsigargin interferes not only with Ca(2+) binding and phosphoenzyme formation with ATP but also with phosphoenzyme formation by utilization of P(i) even though this reaction does not require Ca(2+). It is concluded that NF1058 and CLT inhibit SERCA by stabilization of an E(2) state that, as opposed to that obtained with thapsigargin, retains the functional ability to form E(2)-P by reacting with P(i).

Indexed as

Adenosine TriphosphateAminoquinolinesAnimalsCalciumClotrimazoleDose-Response Relationship, DrugElectrophysiologyEnzyme InhibitorsHydrolysisInhibitory Concentration 50KineticsMembrane ProteinsModels, ChemicalPhosphorylationRabbitsSarcoplasmic Reticulum4-aminoquinolineAdenosine TriphosphateAminoquinolinesCalciumClotrimazoleEnzyme InhibitorsMembrane ProteinsSarcoplasmic Reticulum Calcium-Transporting ATPases

Identifiers

PMID21914795
PMCPMC3207476
OpenAlexW2012103310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.